Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England | Bennett Institute for Applied Data Science

Paper information

Authors: Millie Green,

Helen Curtis,

Will Hulme,

Elizabeth Williamson,

Helen McDonald,

Krishnan Bhaskaran,

Christopher Rentsch,

Anna Schultze,

Brian MacKenna,

Viyaasan Mahalingasivam,

Laurie Tomlinson,

Alex Walker,

Louis Fisher,

Jon Massey,

Colm Andrews,

Lisa Hopcroft,

Caroline Morton,

Richard Croker,

Jess Morley,

Amir Mehrkar,

Seb Bacon,

Dave Evans,

Peter Inglesby,

George Hickman,

Tom Ward,

Simon Davy,

Rohini Mathur,

John Tazare,

Rosalind Eggo,

Kevin Wing,

Angel Wong,

Harriet Forbes,

Chris Bates,

Jonathan Cockburn,

John Parry,

Frank Hester,

Sam Harper,

Ian Douglas,

Stephen Evans,

Liam Smeeth,

Ben Goldacre
Citation: The OpenSAFELY Collaborative., Green, A., Curtis, H. et al. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Med 20, 243 (2022). https://doi.org/10.1186/s12916-022-02422-0
DOI: 10.1186/s12916-022-02422-0
Preprint: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY
Categories: OpenSAFELY

Abstract

Background

While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have experienced COVID-19 vaccine breakthroughs could be hugely important in helping to determine who may be at greatest risk.

Methods

With the approval of NHS England, we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY-TPP database of fully vaccinated individuals, linked to secondary care and death registry data and described the characteristics of those experiencing COVID-19 vaccine breakthroughs.

Results

As of 1st November 2021, a total of 15,501,550 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 149 days (IQR: 107–179). From within this population, a total of 579,780 (<4%) individuals reported a positive SARS-CoV-2 test. For every 1000 years of patient follow-up time, the corresponding incidence rate (IR) was 98.06 (95% CI 97.93–98.19). There were 28,580 COVID-19-related hospital admissions, 1980 COVID-19-related critical care admissions and 6435 COVID-19-related deaths; corresponding IRs 4.77 (95% CI 4.74–4.80), 0.33 (95% CI 0.32–0.34) and 1.07 (95% CI 1.06–1.09), respectively. The highest rates of breakthrough COVID-19 were seen in those in care homes and in patients with chronic kidney disease, dialysis, transplant, haematological malignancy or who were immunocompromised.

Conclusions

While the majority of COVID-19 vaccine breakthrough cases in England were mild, some differences in rates of breakthrough cases have been identified in several clinical groups. While it is important to note that these findings are simply descriptive and cannot be used to answer why certain groups have higher rates of COVID-19 breakthrough than others, the emergence of the Omicron variant of COVID-19 coupled with the number of positive SARS-CoV-2 tests still occurring is concerning and as numbers of fully vaccinated (and boosted) individuals increases and as follow-up time lengthens, so too will the number of COVID-19 breakthrough cases. Additional analyses, to assess vaccine waning and rates of breakthrough COVID-19 between different variants, aimed at identifying individuals at higher risk, are needed.